leadf
logo-loader
viewHumanigen, Inc.

Humanigen prices underwritten public offering of 8 million shares to raise $68M as it preps for Nasdaq debut

The company intends to use the net proceeds to support its manufacturing, production and commercial preparation for lenzilumab as a potential therapy for COVID-19 patients

covid
Each share is priced at $8.50 and the offering is expected to close on or about September 22

Humanigen Inc (NASDAQ:HGEN) (OTCQB:HGEND), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab, has priced its underwritten public offering of 8 million shares of common stock to raise about $68 million. 

The California-based company intends to use the net proceeds to support its manufacturing, production and commercial preparation activities relating to lenzilumab as a potential therapy for COVID-19 patients and for general corporate purposes.

In a statement Friday, Humanigen said each share is priced at $8.50 and the offering is expected to close on or about September 22.

READ: Humanigen and Lonza reveal collaboration to expand manufacturing COVID-19 therapeutic candidate lenzilumab 

Humanigen also granted the underwriters a 30-day option to purchase up to an additional 1.2 million shares at the public offering price, less underwriting discounts and commissions.

JP Morgan and Jefferies are acting as joint book-running managers for the offering. Bryan, Garnier & Co is acting as the European lead manager and HC Wainwright & Co, National Securities Corporation and Roth Capital Partners are acting as co-managers.

Lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate, is being evaluated in an ongoing Phase III trial and was selected by the National Institutes of Health for its COVID-19 Big Effect Trial. 

Meanwhile, Humanigen's stock will commence trading on the Nasdaq Capital Market on Friday under the symbol "HGEN."

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Humanigen, Inc.

Price: - -

OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Humanigen announces 71.8 million dollars in financing

Humanigen (OTCQB: HGEN) Chairman and CEO Cameron Durant joined Steve Darling from Proactive Vancouver with news the company has secured almost 72 million dollars in financing. Durant discusses those making up that financing which is a big part of the story..

on 3/6/20

2 min read